AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

Trial Identifier: D9971C00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: May 2026
Study Completion Date: May 2026
Condition: Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Nedlands, AU, 6009
DE Köln, DE, 50937
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28041
FR Creteil, FR, 94010
FR Lille, FR, 59000
FR PIERRE BENITE, FR, 69310
FR Villejuif Cedex, FR, 94805
GB Manchester, GB, M20 4BX
GB Oxford, GB, OX3 7LE
IT Alessandria, IT, 15100
IT Bologna, IT, 40138
IT Milan, IT, 20141
KR Seoul, KR, 06351
KR Seoul, KR, 03080
US, FL Miami, FL, US, 33136
US, MA Boston, MA, US, 02215
US, PA Philadelphia, PA, US, 19104
US, TX Houston, TX, US, 77030